BRAF and thyroid cancer: The rationale for the latter approach was established in a preclinical study by Chakravarty et al., which demonstrated that thyroid cancers driven by BRAF V600E mutations in a mouse model exhibit profound suppression of sodium-iodide symporter expression, rendering them resistant to RAI.